3D Bioprinting Market by Technology (Magnetic Levitation, Inkjet-Based, Syringe-Based, Laser-Based, and Others), Material (Hydrogels, Living Cells, Extracellular Matrices, and Other), Components (Bioprinters and Bioinks), Application (Medical, Dental, Biosensors, Consumer/Personal Product Testing, Bio inks, and Food and Animal Products), End Users (Pharmaceutical Companies, Research & Academic Institutions, Medical Device Manufacturers, and Contract Research Organizations) : Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026437 | Pages: 100 | Industry: Medical Device | Date: Sep 2022 | Type: Global

The market crossed the US$ 1.91 billion mark in 2022 and is expected to hit US$ 6.26 billion by 2030, recording a CAGR of 15.1% during the forecast period.

The Bioprinter segment has been significantly growing with the high adoption of 3D Bioprinting.

The rising prevalence of cardiovascular diseases is a cause of mortality and morbidity worldwide. Compared to traditional therapeutic strategies, the 3D printing technique is advanced for creating complicated cardiovascular implants with features like biomimetic recapitulating, native physiochemical, and biomechanical characteristics of the cardiovascular system. Adult cardiovascular tissue cannot repair or renew after injury due to limited regenerative capacity. In the end stages of cardiovascular disease, replacement or transplantation is the only option.

 According to John Muir Health, an integrated system of doctors, hospitals, and other services, more than 80,000 heart valve replacements and over 600,000 vascular implantations are performed annually in the United States alone, costing approximately U.S. $200 billion. The Cardiac implantation methods are majorly limited by the shortage of available donors and immune rejection. Mechanical mismatch, blood coagulation, and limited durability are other significant concerns. As a promising alternative, cardiovascular tissue engineering is being explored to restore cardiac functionality and replace abnormal or necrotic tissues.

Within the report, the market is segmented into technology, material, components, application, and end-user. By technology, it is segmented into magnetic levitation, inkjet-based, syringe-based, laser-based, and others. The material market is segmented by hydrogels, living cells, extracellular matrices, etc. By application, it is segmented into medical, dental, biosensors, consumer/personal product testing, bioinks, and food and animal products. End users are segmented into pharmaceutical companies, research & academic institutions, medical device manufacturers, and contract research organizations. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South and Central America, and Middle East & Africa.

Get more information on this report :

Rising adoption of 3D printing technology in pharmaceutical companies for drug discovery and development

3D bioprinting is the technique that utilizes 3D printing technology to print biological tissues by combining cells, growth factors, or biomaterials. 3D printing utilizes the bio-ink to fabricate tissues like structure layer by layer, which is t later used in tissue engineering and the medical field. It covers a broad range of biomaterials and biotreatment. It prints tissues and organs to help research and potential treatment. Bioprinting follows three steps: pre-bioprinting, bioprinting, and post-bioprinting. Researchers have developed approaches to producing living organs with appropriate biological and mechanical properties. 3D bioprinting is based on three main methods: Biomimicry, autonomous self-assembly, and mini tissue building blocks.

Many pharmaceutical companies are adopting 3D bioprinting products and technologies in drug discovery and development. The efficiency of the drug is measured by the method of drug delivery. 3D Bioprinting technology in recent years has been repurposed for pharmaceutical applications. Recently tablets have been used for personalized dosage and combining several dosages into one pill. Additionally, future development will include sustained drug release and targeted tissue healing. The 3D bioprinting method enables pharmaceutical companies to test drugs more safely and at a lower cost than traditional drug testing. 3D bioprinting overcomes the limitations of conventional formulation methods of drug preparation by tailoring, micro structuring, and changing composition in different regions. Due to this 3D bioprinting market will witness a boost in the market.

Rising prevalence of chronic kidney disease

According to Health Resources & Services Administration, on average living, a donor provides 6000 organs per year, and there are about 8000 deceased donors annually, which provide 3.5 organs each. Every day 17 people die waiting for an organ transplant. According to the data, 90% of them needed a kidney. The rising prevalence of chronic renal disease will boost the market. It is estimated that it affects 37 million people in the U.S. alone, i.e., 15 % of the total population. Chronic kidney disease (CKD) is when the kidney loses its ability to filter toxins from the body. The toxins then remain in the body. In the early stages, the symptoms are not visible, but as the disease progresses, there is a buildup in the blood, and the person starts feeling sick. Other problems include high blood pressure, anemia, weak bones, poor nutritional health, and nerve damage.

The significant advantage of 3D-printed kidneys is that there is no room for organ rejection as the 3D-printed organ is made from the patient’s stem cells. Physical rejection of donated organs is the leading cause of the post-operative death of transplant patients. A rise in the prevalence of CKD worldwide and advantages linked with 3D Bioprinting organs will help propel the market.

Recent strategic developments in the 3D bioprinting market

The 3D bioprinting market has undergone several significant consequences, and a few of these have been mentioned below:

  • In September 2021, Envision TEC and Covestro announced their collaboration on material printer solutions to accelerate the adoption of industrial 3D printing. The aim is to lower the entry barriers for companies looking to adopt 3D printing for producing molds for low volumes or parts with detailed features faster and more economically
  • In December 2021, Inventia Life Science raised the U.S. $25m and launched ‘Rastrum.’ Australian 3D bioprinting specialist Inventia Life Science has announced the closure of a Series B funding round that has seen it raise US$25 million

Several players drive the 3D bioprinting market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Envision TEC, Inc., Organovo Holdings, Inc., Inventia Life Science PTY LTD, Poietis, Vivax Bio, LLC; Allevi, Inc., Cyfuse Biomedical K.K., 3D Bioprinting Solutions, Cellink Global, and Bico group ab, are among few players operating in the market.

The target audience for the report:

  • Raw material providers
  • 3D Bioprinter manufacturers
  • Pharmaceutical Companies
  • Contract Research Organizations
  • Venture capitalists, private equity firms, and start-up companies
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented based on:

  • Technology:
    • Magnetic Levitation
    • Inkjet-based
    • Syringe-based
    • Laser-based
    • Others
  • Material:
    • Hydrogels
    • Living cells
    • Extracellular matrices
    • Other
  • Components
    • Bioprinters
    • Bio inks
  • Application:
    • Medical
    • Dental
    • Biosensors
    • Consumer/Personal Product Testing
    • Bioinks
    • Food and Animal Product
  •  End User:
    • Pharmaceutical Companies
    • Research & Academic Institutions
    • Medical Device Manufacturers
    • Contract Research Organization
  • Region:
    • North America
    • Europe
    • Asia Pacific (APAC)
    • Middle East & Africa (MEA)
    • South & Central America (SCAM)
  • Companies Profiled:
    • EnvisionTEC, Inc.
    • Organovo Holdings, Inc.
    • Inventia Life Science PTY LTD
    • Poietis
    • Vivax Bio, LLC
    • Allevi, Inc.
    • Cyfuse Biomedical K.K.
    • 3D Bioprinting Solutions
    • Cellink Global
    • Bico group ab,

Companies profiled:
- EnvisionTEC, Inc.
- Organovo Holdings, Inc.
- Inventia Life Science PTY LTD
- Poietis
- Vivax Bio, LLC
- Allevi, Inc.
- Cyfuse Biomedical K.K.
- 3D Bioprinting Solutions
- Cellink Global
- Bico group ab,


Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000